GreenLight Biosciences Holdings PBC (GRNA) Stock Price, Forecast & Analysis
NASDAQ:GRNA • US39536G1058
GRNA Key Statistics, Chart & Performance
The current stock price of GRNA is 0.2995 USD. In the past month the price increased by 1.49%. In the past year, price decreased by -85.53%.
GRNA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRNA. When comparing the yearly performance of all stocks, GRNA is a bad performer in the overall market: 95.46% of all stocks are doing better.
GRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRNA. GRNA may be in some trouble as it scores bad on both profitability and health.
GRNA Financial Highlights
Over the last trailing twelve months GRNA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -5.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.49 |
GRNA Forecast & Estimates
7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.
For the next year, analysts expect an EPS growth of 26.28% and a revenue growth 167.93% for GRNA
GRNA Ownership
GRNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRNA
Company Profile
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Company Info
GreenLight Biosciences Holdings PBC
29 Hartwell Avenue
Lexington MASSACHUSETTS US
Employees: 262
Phone: 16176168188.0
GreenLight Biosciences Holdings PBC / GRNA FAQ
What does GreenLight Biosciences Holdings PBC do?
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
What is the current price of GRNA stock?
The current stock price of GRNA is 0.2995 USD. The price decreased by -0.03% in the last trading session.
Does GreenLight Biosciences Holdings PBC pay dividends?
GRNA does not pay a dividend.
What is the ChartMill rating of GreenLight Biosciences Holdings PBC stock?
GRNA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is GreenLight Biosciences Holdings PBC (GRNA) stock traded?
GRNA stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for GreenLight Biosciences Holdings PBC?
GreenLight Biosciences Holdings PBC (GRNA) operates in the Health Care sector and the Biotechnology industry.
How many employees does GreenLight Biosciences Holdings PBC have?
GreenLight Biosciences Holdings PBC (GRNA) currently has 262 employees.